AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.

The company invested $445 million to expand the facility, it said. The unveiling follows the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia.  

The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.

The facility supplies the drug to more than 50 countries worldwide. AstraZeneca said that through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added, along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities, and administrative space.

The increased investment in the U.S. by drugmakers follows President Donald Trump’s push to move pharmaceutical manufacturing to American soil. Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products effective October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.

On Stocktwits, retail sentiment around AZN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.

AZN stock is up by 29% this year and by about 8% over the past 12 months. 

Read also: Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on